Clinical trial • Phase I • Oncology

Clinical trial in Breast cancer | Colorectal cancer | Prostate cancer | Endometrial cancer | Metastatic neoplasm

Phase I trial for Breast cancer | Colorectal cancer | Prostate cancer | Endometrial cancer | Metastatic neoplasm. 368 participants.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Breast cancer | Colorectal cancer | Prostate cancer | Endometrial cancer | Metastatic neoplasm
Trial Stage
Phase I

Key dates

Initial CTIS Submission Date
29-12-2025
First CTIS Authorization Date
05-03-2026

Trial design

Phase I trial across 1 site in Germany.

Target Sample Size
368

Eligibility

Recruits 368 No vulnerable population selected (isVulnerablePopulationSelected=false). Consent/assent handling not specified..

Vulnerable Population
No vulnerable population selected (isVulnerablePopulationSelected=false). Consent/assent handling not specified.

Recruitment

Planned Sample Size
368
Recruitment Window Months
107
Consent Approach
Not specified. Population: adults (isVulnerablePopulationSelected=false). Consent procedures and assent not described.

Geography

Total Number Of Sites
1
Total Number Of Participants
368

Germany

Earliest CTIS Part Ii Submission Date
23-02-2026
Latest Decision Or Authorization Date
01-04-2026
Processing Time Days
37
Number Of Sites
1
Number Of Participants
53

Sites

Site Name
Universitaetsklinikum Essen AöR
Department Name
Department of Nuclear Medicine
Principal Investigator Name
Ken Herrmann
Principal Investigator Email
ken.herrmann@uk-essen.de
Contact Person Name
Ken Herrmann
Contact Person Email
ken.herrmann@uk-essen.de
Number Of Participants
53

Sponsor

Primary sponsor

Full Name
Eli Lilly & Co.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Related trials

Other published trials that may interest you.